Patents Assigned to Biovitrum AB (publ.)
-
Publication number: 20140186921Abstract: The invention relates to a process for recovering and purifying bile salt-stimulated lipase (BSSL) in a solution which contains impurities, said process comprising the steps: (i) applying BSSL to a hydrophobic interaction chromatography (HIC) resin; (ii) removing impurities by washing said HIC resin with a wash composition having a pH in the range from 4 to 5; and (iii) recovering BSSL from said HIC resin.Type: ApplicationFiled: May 15, 2012Publication date: July 3, 2014Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)Inventors: Thomas Strömquist, Susanne Wood
-
Publication number: 20140018298Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.Type: ApplicationFiled: February 9, 2012Publication date: January 16, 2014Applicant: Swedish Orphan Biovitrum AB (Publ)Inventors: Jonas Fransson, Ebba Florin-Robertsson
-
Publication number: 20130158266Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: ApplicationFiled: February 15, 2013Publication date: June 20, 2013Applicant: BIOVITRUM AB (PUBL)Inventor: Biovitrum AB (publ)
-
Patent number: 8410113Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: GrantFiled: September 16, 2011Date of Patent: April 2, 2013Assignee: Biovitrum AB (publ)Inventors: Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren, Bruce Fleck
-
Patent number: 8304387Abstract: The present invention provides long-term stable formulations of lyophilized keratinocyte growth factor and methods for making a lyophilized composition comprising keratinocyte growth factor.Type: GrantFiled: December 12, 2005Date of Patent: November 6, 2012Assignee: Swedish Orphan Biovitrum AB (publ)Inventors: Michael J. Treuheit, Vasumathi Dharmavaram, Judith Purtell, Suzanne E. Roy
-
Publication number: 20120100127Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Publication number: 20120100126Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Patent number: 8030316Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: GrantFiled: June 17, 2010Date of Patent: October 4, 2011Assignee: Biovitrum AB (Publ)Inventors: Tom Fleck, Bruce Fleck, legal representative, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
-
Patent number: 7812017Abstract: The present invention relates to novel compounds of formula (I): wherein m, n, R0, R1, R2, R3 and R4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.Type: GrantFiled: July 3, 2007Date of Patent: October 12, 2010Assignee: Biovitrum AB (publ.)Inventors: Johan Angbrant, Rune Ringom, Kristin Hammer, Erik Ringberg, Bengt Lindqvist, Gary Johansson, Peter Brandt, Katarina Beierlein, Björn M Nilsson
-
Publication number: 20100022590Abstract: The present invention relates to novel isoxazole compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides thereof, which are modulators of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the preparation of a medicament for the treatment of glaucoma.Type: ApplicationFiled: January 15, 2009Publication date: January 28, 2010Applicant: BIOVITRUM AB (publ.)Inventors: Styrbjörn Byström, Martin Haraldsson, Lars Johansson, Jan Tejbrant
-
Patent number: 7582767Abstract: The present invention relates to compounds of the formula (I), wherein R1 and R2 are as defined in the description; to pharmaceutical formulations comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and/or body weight gain.Type: GrantFiled: June 5, 2006Date of Patent: September 1, 2009Assignee: Biovitrum AB (publ.)Inventors: Patrizia Caldirola, Gary Johansson, Lori Sutin
-
Publication number: 20080293694Abstract: The present invention relates to novel compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.Type: ApplicationFiled: March 13, 2008Publication date: November 27, 2008Applicant: Biovitrum AB (publ.)Inventors: Johan Angbrant, Peter Brandt, Rune Ringom, Bengt Lindqvist
-
Publication number: 20080255153Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, which are useful as inhibitors of human stearoyl-CoA desaturase (SCD). The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, metabolic syndrome, neurological diseases, immune disorders, cancer and various skin diseases.Type: ApplicationFiled: March 27, 2008Publication date: October 16, 2008Applicant: BIOVITRUM AB (publ)Inventors: Ulf Bremberg, Auri Linden, Thomas Lundback, Jonas Nilsson, Marie Wiik, Magnus Bergner, Peter Brandt, Kristin Hammer, Rune Ringom